Method of enhancing innate immune responses against a tumor comprising administering lymphocytic choriomeningitis virus (LCMV)
The invention relates to arenaviruses for use in the treatment and/or prevention of tumors and also a method for preparing arenaviruses with (improved) tumor-regressive properties.
1. A method of enhancing an innate immune response in a subject bearing a malignant tumor, comprising:
administering to the subject a lymphocytic choriomeningitis virus (LCMV) that increases secretion of interferon-α by innate (congenital) immune cells, thereby activating the innate (congenital) immune cells,
wherein the sequences of the L- and S-ribonucleic acids of the LCMV are selected from the group consisting of WE, Clone 13 and Docile L- and S-ribonucleic acid sequences.
2. The method of claim 1 , wherein the LCMV has been subjected to serial passage in a tumor cell line of the same type as the tumor prior to the administering step.
3. The method of claim 1 , wherein the tumor is selected from the group consisting of carcinoma, melanoma, blastoma, lymphoma, and sarcoma.
4. The method of claim 1 , wherein the LCMV comprises an S-ribonucleic acid sequence according to SEQ ID No. 5 or ambisense sequence thereof, or an L-ribonucleic acid sequence according to SEQ ID No. 6 or ambisense sequence thereof.
5. The method of claim 1 , wherein the L- and S-ribonucleic acids of the LCMV are WE L- and S-ribonucleic acids.
6. The method of claim 1 , wherein the subject is a human.
7. A method according to claim 1 ,
wherein the tumor is a solid tumor.
8. The method of claim 7 , wherein the LCMV has been subjected to serial passage in a tumor cell line of the same type as the tumor prior to the administering step.
9. The method of claim 7 , wherein the tumor is carcinoma.
10. The method of claim 7 , wherein the tumor is melanoma.
11. The method of claim 7 , wherein the LCMV comprises an S-ribonucleic acid sequence according to SEQ ID No. 5 or ambisense sequence thereof, or an L-ribonucleic acid sequence according to SEQ ID No. 6 or ambisense sequence thereof.
12. The method of claim 7 , wherein the L- and S-ribonucleic acids of the LCMV are WE L- and S-ribonucleic acids.
13. The method of claim 7 , wherein the subject is a human.